Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up

Monika Kozieł; Michał Mazurek; Christine Teutsch; Hans-Christoph Diener; Sergio J Dubner; Jonathan L Halperin; Chang-Sheng Ma; Kenneth J Rothman; Axel Brandes; Miney Paquette; Kristina Zint; Lionel Riou França; Shihai Lu; Dorothee B Bartels; Menno V Huisman; Gregory Y H Lip

doi:10.3390/jcm9061969

Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up

Monika Kozieł, Michał Mazurek, Christine Teutsch, Hans-Christoph Diener, Sergio J Dubner, Jonathan L Halperin, Chang-Sheng Ma, Kenneth J Rothman, Axel Brandes, Miney Paquette, Kristina Zint, Lionel Riou França, Shihai Lu, Dorothee B Bartels, Menno V Huisman, Gregory Y H Lip

Research output: Contribution to journal › Journal article › Research › peer-review

11 Citations (Scopus)

25 Downloads (Pure)

Abstract

BACKGROUND: We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients and to estimate the difference in therapy persistence depending on NOAC dosing regimen (once daily (QD) vs. twice daily (BID)).

METHODS: Consecutive patients were followed for 1 year in phase III of the GLORIA-AF registry. Drug persistence was defined as the use of OAC without any discontinuation in >30 days or switching to alternative therapy.

RESULTS: Among 21,109 eligible patients in phase III, 17,266 patients who were prescribed OAC at baseline and those who took ≥1 OAC dose were included. The 1-year proportion of patients receiving NOAC and VKA who persisted on treatment was 80% and 75%, respectively. The 1-year persistence with NOACs BID and NOACs QD was 81% and 80%, respectively. Female gender, hypertension, older age, alcohol use, permanent, asymptomatic, and minimally symptomatic AF were associated with better OAC persistence. Region, medication usage predisposing to bleeding, being a current smoker, treatment reimbursement, and proton pump inhibitors were associated with lower OAC persistence.

CONCLUSIONS: Drug persistence was higher with NOACs (1-year persistence was 80%) than with VKAs (75%). There was little difference in 1-year persistence between NOAC dosing regimens.

Original language	English
Article number	1969
Journal	Journal of Clinical Medicine
Volume	9
Issue number	6
ISSN	2077-0383
DOIs	https://doi.org/10.3390/jcm9061969
Publication status	Published - 23 Jun 2020

Access to Document

10.3390/jcm9061969Licence: CC BY 4.0

Koziel et al (2020) Persistence with Anticoagulation for Atrial FibrillationFinal published version, 896 KBLicence: CC BY 4.0

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Kozieł, M., Mazurek, M., Teutsch, C., Diener, H-C., Dubner, S. J., Halperin, J. L., Ma, C-S., Rothman, K. J., Brandes, A., Paquette, M., Zint, K., França, L. R., Lu, S., Bartels, D. B., Huisman, M. V., & Lip, G. Y. H. (2020). Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. Journal of Clinical Medicine , 9(6), Article 1969. https://doi.org/10.3390/jcm9061969

@article{252e5f42850c48a9996320c481819001,

title = "Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up",

abstract = "BACKGROUND: We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients and to estimate the difference in therapy persistence depending on NOAC dosing regimen (once daily (QD) vs. twice daily (BID)).METHODS: Consecutive patients were followed for 1 year in phase III of the GLORIA-AF registry. Drug persistence was defined as the use of OAC without any discontinuation in >30 days or switching to alternative therapy.RESULTS: Among 21,109 eligible patients in phase III, 17,266 patients who were prescribed OAC at baseline and those who took ≥1 OAC dose were included. The 1-year proportion of patients receiving NOAC and VKA who persisted on treatment was 80% and 75%, respectively. The 1-year persistence with NOACs BID and NOACs QD was 81% and 80%, respectively. Female gender, hypertension, older age, alcohol use, permanent, asymptomatic, and minimally symptomatic AF were associated with better OAC persistence. Region, medication usage predisposing to bleeding, being a current smoker, treatment reimbursement, and proton pump inhibitors were associated with lower OAC persistence.CONCLUSIONS: Drug persistence was higher with NOACs (1-year persistence was 80%) than with VKAs (75%). There was little difference in 1-year persistence between NOAC dosing regimens.",

author = "Monika Kozie{\l} and Micha{\l} Mazurek and Christine Teutsch and Hans-Christoph Diener and Dubner, {Sergio J} and Halperin, {Jonathan L} and Chang-Sheng Ma and Rothman, {Kenneth J} and Axel Brandes and Miney Paquette and Kristina Zint and Fran{\c c}a, {Lionel Riou} and Shihai Lu and Bartels, {Dorothee B} and Huisman, {Menno V} and Lip, {Gregory Y H}",

year = "2020",

month = jun,

day = "23",

doi = "10.3390/jcm9061969",

language = "English",

volume = "9",

journal = "Journal of Clinical Medicine ",

issn = "2077-0383",

publisher = "MDPI",

number = "6",

}

Kozieł, M, Mazurek, M, Teutsch, C, Diener, H-C, Dubner, SJ, Halperin, JL, Ma, C-S, Rothman, KJ, Brandes, A, Paquette, M, Zint, K, França, LR, Lu, S, Bartels, DB, Huisman, MV & Lip, GYH 2020, 'Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up', Journal of Clinical Medicine , vol. 9, no. 6, 1969. https://doi.org/10.3390/jcm9061969

TY - JOUR

T1 - Persistence with Anticoagulation for Atrial Fibrillation

T2 - Report from the GLORIA-AF Phase III 1-Year Follow-up

AU - Kozieł, Monika

AU - Mazurek, Michał

AU - Teutsch, Christine

AU - Diener, Hans-Christoph

AU - Dubner, Sergio J

AU - Halperin, Jonathan L

AU - Ma, Chang-Sheng

AU - Rothman, Kenneth J

AU - Brandes, Axel

AU - Paquette, Miney

AU - Zint, Kristina

AU - França, Lionel Riou

AU - Lu, Shihai

AU - Bartels, Dorothee B

AU - Huisman, Menno V

AU - Lip, Gregory Y H

PY - 2020/6/23

Y1 - 2020/6/23

N2 - BACKGROUND: We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients and to estimate the difference in therapy persistence depending on NOAC dosing regimen (once daily (QD) vs. twice daily (BID)).METHODS: Consecutive patients were followed for 1 year in phase III of the GLORIA-AF registry. Drug persistence was defined as the use of OAC without any discontinuation in >30 days or switching to alternative therapy.RESULTS: Among 21,109 eligible patients in phase III, 17,266 patients who were prescribed OAC at baseline and those who took ≥1 OAC dose were included. The 1-year proportion of patients receiving NOAC and VKA who persisted on treatment was 80% and 75%, respectively. The 1-year persistence with NOACs BID and NOACs QD was 81% and 80%, respectively. Female gender, hypertension, older age, alcohol use, permanent, asymptomatic, and minimally symptomatic AF were associated with better OAC persistence. Region, medication usage predisposing to bleeding, being a current smoker, treatment reimbursement, and proton pump inhibitors were associated with lower OAC persistence.CONCLUSIONS: Drug persistence was higher with NOACs (1-year persistence was 80%) than with VKAs (75%). There was little difference in 1-year persistence between NOAC dosing regimens.

AB - BACKGROUND: We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients and to estimate the difference in therapy persistence depending on NOAC dosing regimen (once daily (QD) vs. twice daily (BID)).METHODS: Consecutive patients were followed for 1 year in phase III of the GLORIA-AF registry. Drug persistence was defined as the use of OAC without any discontinuation in >30 days or switching to alternative therapy.RESULTS: Among 21,109 eligible patients in phase III, 17,266 patients who were prescribed OAC at baseline and those who took ≥1 OAC dose were included. The 1-year proportion of patients receiving NOAC and VKA who persisted on treatment was 80% and 75%, respectively. The 1-year persistence with NOACs BID and NOACs QD was 81% and 80%, respectively. Female gender, hypertension, older age, alcohol use, permanent, asymptomatic, and minimally symptomatic AF were associated with better OAC persistence. Region, medication usage predisposing to bleeding, being a current smoker, treatment reimbursement, and proton pump inhibitors were associated with lower OAC persistence.CONCLUSIONS: Drug persistence was higher with NOACs (1-year persistence was 80%) than with VKAs (75%). There was little difference in 1-year persistence between NOAC dosing regimens.

U2 - 10.3390/jcm9061969

DO - 10.3390/jcm9061969

M3 - Journal article

C2 - 32586056

SN - 2077-0383

VL - 9

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 6

M1 - 1969

ER -

Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up

Abstract

Access to Document

AUB Link

Fingerprint

Cite this